Oppenheimer analyst Steven Lichtman assigned a Buy rating to Motus Gi Holdings (MOTS) today and set a price target of $2.25. The company’s shares closed last Thursday at $1.50.
According to TipRanks.com, Lichtman is a 5-star analyst with an average return of 17.1% and a 56.7% success rate. Lichtman covers the Healthcare sector, focusing on stocks such as Zimmer Biomet Holdings, Merit Medical Systems, and Integra Lifesciences.
Motus Gi Holdings has an analyst consensus of Strong Buy, with a price target consensus of $2.25, implying a 49.0% upside from current levels. In a report released yesterday, Colliers Securities also reiterated a Buy rating on the stock with a $2.50 price target.
See today’s analyst top recommended stocks >>
Based on Motus Gi Holdings’ latest earnings release for the quarter ending September 30, the company reported a quarterly revenue of $33K and GAAP net loss of $3.94 million. In comparison, last year the company earned revenue of $3,000 and had a GAAP net loss of $5.2 million.
Based on the recent corporate insider activity of 25 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of MOTS in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Motus GI Holdings, Inc. is a medical technology company, which is dedicated to improving endoscopy outcomes and experiences. It engages in the development and commercialization of the Pure-Vu System to improve the colonoscopy experience and assist in the early detection and prevention of colorectal cancer and other diseases of the rectum and colon. The company was founded in September, 2016 and is headquartered in Fort Lauderdale, FL.